A Study to Evaluate Efficacy, Safety, and Pharmacokinetics of XEMBIFY ® Plus Standard Medical Treatment (SMT) Compared to Placebo Plus SMT to Prevent Infections in Participants With Hypogammaglobulinemia and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia

Conditions:   Hypogammaglobulinemia;   Bacterial Infections;   B-cell Chronic Lymphocytic Leukemia Interventions:   Drug: Xembify;   Drug: Placebo Sponsor:   Grifols Therapeutics LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials